drugset / Trial / NCT01497145

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

NCT01497145

Phase 2 Completed 45 enrolled Kyowa Kirin, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, Randomized, Open-Label, Parallel, Comparative, Dose-Response Study to Evaluate the Efficacy and Safety study of KRN321 of subcutaneous injection in Adult Subjects with Low- or Intermediate-1-Risk Myelodysplastic Syndrome.

Timeline

Start
2011-12
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic Subcutaneous